Taysha Gene Therapies, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $0 | — |
| FY2020 | — | $251.3M | $251.3M |
| FY2021 | $37.2M | $95.4M | $149.1M |
| FY2022 | $38.0M | $949.0K | $87.9M |
| FY2023 | $40.5M | $74.9M | $143.9M |
| FY2024 | $43.9M | $71.5M | $139.0M |
| FY2025 | $50.1M | $246.9M | $319.8M |